Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – X-ray contrast imaging agent
Reexamination Certificate
2002-10-25
2004-08-10
Hartley, Michael G. (Department: 1616)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
X-ray contrast imaging agent
C424S009520, C424S501000, C516S011000, C516S077000
Reexamination Certificate
active
06773696
ABSTRACT:
BACKGROUND OF THE INVENTION
is Computed tomography (CT) is a widespread diagnostic imaging method which measures, in its imaging process, the radiodensity (electron density) of matter. This radiodensity is depicted using CT in terms of Hounsefield Units (HU). Hounsefield Units, named after the inventor of the first CT scanner, reflect the relative absorption of CT X-rays by matter, the absorption being directly proportional to the electron density of that matter. Water, for example, has a value of 0 HU, air a value of −1000 HU, and dense cortical bone a value of +1000 HU. Because of the similarity in density of various tissues in the body, however, contrast agents have been sought to change the relative density of different tissues, and improve the overall diagnostic efficacy of this imaging method.
In the search for contrast agents for CT, researchers have generally sought to develop agents that will increase electron density in certain areas of a region of the body (positive contrast agents). Barium and iodine compounds, for example, have been developed for this purpose. For the gastrointestinal tract, barium sulfate is used extensively to increase the radiodensity of the bowel lumen on CT scans. Iodinated water soluble contrast media are also used to increase density within the gastro-intestinal tract, but are not used as commonly as the barium compounds, primarily because the iodine preparations are more expensive than barium and prove less effective in increasing radiodensity within this region of the body.
Despite their widespread use, however, barium and iodine compounds are suboptimally effective as gastro-intestinal contrast agents for CT. For example, if the concentration is too low, there is little contrast. Conversely, if the concentration is too high, then these radiodense contrast agents cause beam hardening artifacts which are seen as streaks on the CT images. It is also difficult to visualize the bowel mucosa with either the barium or iodine contrast agents.
In an attempt to improve upon the efficacy of contrast agents for the gastrointestinal tract, lipid emulsions that are capable of decreasing electron density (negative contrast agents) have been developed. Because lipids have a lower electron density than water, lipids provide a negative density on CT (a negative HU value). While these lipid emulsions appear to be more effective than the barium and iodine agents at improving visual-ization of the mucosa of the bowel, these contrast agents have limitations. First, there is a limitation to the concentration of lipid which a patient can tolerably drink, which puts a limit on the change in density (or HU) which the lipid based CT contrast agent can provide. Lipid emulsions are also frequently expensive. Furthermore, these lipid formulations are generally perishable, which provides for packaging and storage problems.
New and/or better contrast agents for computed tomography imaging are needed. The present invention is directed toward this important end.
SUMMARY OF THE INVENTION
The present invention is directed to computed tomography imaging, and more particularly to the use of a contrast medium comprising a substantially homogeneous aqueous suspension of low density microspheres to image the gastrointestinal region and other body cavities of a patient. In one embodiment, the low density microspheres are gas-filled.
Specifically, the present invention pertains to methods of providing an image of the gastrointestinal region or other body cavities of a patient comprising (i) administering to the patient the aforementioned contrast medium, and (ii) scanning the patient using computed tomography imaging to obtain visible images of the gastrointestinal region or other body cavities.
The present invention is further directed to methods for diagnosing the presence of diseased tissue in the gastrointestinal region or other body cavities of a patient comprising (i) administering to the patient the aforementioned contrast medium, and (ii) scanning the patient using computed tomography imaging to obtain visible images of any diseased tissue in the patient.
The present invention also provides diagnostic kits for computed tomography imaging of the gastrointestinal region or other body cavities which include the subject contrast medium.
REFERENCES:
patent: 3015128 (1962-01-01), Sommerville et al.
patent: 3291843 (1966-12-01), Fritz et al.
patent: 3293114 (1966-12-01), Kenaga et al.
patent: 3479811 (1969-11-01), Walters
patent: 3488714 (1970-01-01), Walters et al.
patent: 3532500 (1970-10-01), Priest et al.
patent: 3557294 (1971-01-01), Dear et al.
patent: 3594326 (1971-07-01), Himmel et al.
patent: 3615972 (1971-10-01), Morehouse et al.
patent: 3650831 (1972-03-01), Jungermann et al.
patent: 3732172 (1973-05-01), Herbig et al.
patent: 3873564 (1975-03-01), Schneider et al.
patent: 3945956 (1976-03-01), Garner
patent: 3960583 (1976-06-01), Netting et al.
patent: 3968203 (1976-07-01), Spitzer et al.
patent: 4027007 (1977-05-01), Messina
patent: 4089801 (1978-05-01), Schneider
patent: 4108806 (1978-08-01), Cohrs et al.
patent: 4138383 (1979-02-01), Rembaum et al.
patent: 4162282 (1979-07-01), Fulwyler et al.
patent: 4179546 (1979-12-01), Garner et al.
patent: 4192859 (1980-03-01), Mackaness et al.
patent: 4224179 (1980-09-01), Schneider
patent: 4229360 (1980-10-01), Schneider et al.
patent: 4265251 (1981-05-01), Tickner
patent: 4276885 (1981-07-01), Tickner et al.
patent: 4303736 (1981-12-01), Torobin
patent: 4310505 (1982-01-01), Baldeschwieler et al.
patent: 4310506 (1982-01-01), Baldeschwieler et al.
patent: 4315514 (1982-02-01), Drewes et al.
patent: 4331654 (1982-05-01), Morris
patent: 4342826 (1982-08-01), Cole
patent: 4344929 (1982-08-01), Bonsen et al.
patent: 4420442 (1983-12-01), Sands
patent: 4421562 (1983-12-01), Sands et al.
patent: 4426330 (1984-01-01), Sears
patent: 4427649 (1984-01-01), Dingle et al.
patent: 4442843 (1984-04-01), Rasor et al.
patent: 4466442 (1984-08-01), Hilmann et al.
patent: 4485193 (1984-11-01), Rubens et al.
patent: 4533254 (1985-08-01), Cook et al.
patent: 4534899 (1985-08-01), Sears
patent: 4540629 (1985-09-01), Sands et al.
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4549892 (1985-10-01), Baker et al.
patent: 4569836 (1986-02-01), Gordon
patent: 4572203 (1986-02-01), Feinstein
patent: 4582756 (1986-04-01), Niinuma et al
patent: 4586512 (1986-05-01), Do-huu et al.
patent: 4603044 (1986-07-01), Geho et al.
patent: 4615879 (1986-10-01), Runge et al.
patent: 4620546 (1986-11-01), Aida et al.
patent: 4646756 (1987-03-01), Watmough et al.
patent: 4657756 (1987-04-01), Rasor et al.
patent: 4658828 (1987-04-01), Dory
patent: 4663161 (1987-05-01), Mannino et al.
patent: 4675310 (1987-06-01), Chapman et al.
patent: 4681119 (1987-07-01), Rasor et al.
patent: 4684479 (1987-08-01), D'Arrigo
patent: 4689986 (1987-09-01), Carson et al.
patent: 4693999 (1987-09-01), Axelsson et al.
patent: 4718433 (1988-01-01), Feinstein
patent: 4722943 (1988-02-01), Melber et al.
patent: 4728575 (1988-03-01), Gamble et al.
patent: 4728578 (1988-03-01), Higgins et al.
patent: 4731239 (1988-03-01), Gordon
patent: 4737323 (1988-04-01), Martin et al.
patent: 4767610 (1988-08-01), Long
patent: 4774958 (1988-10-01), Feinstein
patent: 4775522 (1988-10-01), Clark, Jr.
patent: 4776991 (1988-10-01), Farmer et al.
patent: 4781871 (1988-11-01), West, III et al.
patent: 4789501 (1988-12-01), Day et al.
patent: 4790891 (1988-12-01), Halliday et al.
patent: 4822534 (1989-04-01), Lencki et al.
patent: 4830858 (1989-05-01), Payne et al.
patent: 4834964 (1989-05-01), Rosen
patent: 4844882 (1989-07-01), Widder et al.
patent: 4863717 (1989-09-01), Keana
patent: 4865836 (1989-09-01), Long, Jr.
patent: 4866096 (1989-09-01), Schweighardt
patent: 4877561 (1989-10-01), Iga et al.
patent: 4893624 (1990-01-01), Lele
patent: 4895719 (1990-01-01), Radhakrishnan et al.
patent: 4895876 (1990-01-01), Schweighardt et al.
patent: 4898734 (1990-02-01), Mathiowitz et al.
patent: 4900540 (1990-02-01), Ryan et al.
patent: 4918065 (1990-04-01), Stindl et al.
patent: 4919895 (1990-04-
Bristol-Myers Squibb Medical Imaging, Inc.
Golian Paul D.
Hartley Michael G.
Volles Warren K.
Woodcock & Washburn LLP
LandOfFree
Contrast agent comprising low density microspheres does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Contrast agent comprising low density microspheres, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Contrast agent comprising low density microspheres will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3354808